ALDEYRA THERAPEUTICS, INC. Cash and Restricted Cash
ALDEYRA THERAPEUTICS, INC. (ALDX) had Cash and Restricted Cash of $45.09 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45.09M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $65.00M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.04M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $59.34M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $45.09M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $65.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $70.04M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $59.34M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $41.24M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $50.35M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $54.53M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $68.12M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $71.03M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $102.49M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $142.82M 10-K · filed 2026-02-27 |
| 2023-09-30 | $143.33M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $151.68M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $165.03M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $144.42M 10-K · filed 2025-02-28 |
| 2022-09-30 | $128.65M 10-Q · filed 2023-11-03 |
| 2022-06-30 | $121.01M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $158.91M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $229.79M 10-K · filed 2024-03-07 |
| 2021-09-30 | $241.37M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $249.74M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $138.44M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $77.86M 10-K · filed 2023-03-09 |
| 2020-09-30 | $86.18M 10-Q · filed 2021-10-28 |
| 2020-06-30 | $60.69M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $38.54M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $44.43M 10-K · filed 2022-03-17 |
| 2019-09-30 | $51.60M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $39.40M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $44.30M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $47.36M 10-K · filed 2021-03-11 |
| 2018-09-30 | $18.01M 10-Q · filed 2019-11-07 |
| 2017-12-31 | $20.02M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |